Search
for
Sort by
Research 181–210 of 1000+
- Pathogenic variants affecting peptidyl arginine deiminase 3 and its major substrates underlie central centrifugal cicatricial alopecia
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
- Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesis
- Mapping of a novel locus for keratosis follicularis squamosa on chromosome 7p14.3–7p12.1
- De novo follicular regeneration of the skin by wingless int 3 and bone morphogenetic protein 2 genes introduced into dermal fibroblasts and fibroblast growth factor‐2 protein
- Facial Eruptive Vellus Hair Cysts Occurred after 3% Minoxidil Application
- Variation in Ovine KRTAP13-3 and Its Association with Wool Characteristics in Chinese Tan Sheep
- Pathogenic variants affecting peptidyl arginine deiminase 3 and its major substrates underlie central centrifugal cicatricial alopecia.
- ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
- 4. Bullous/Mucous Membrane
- Cutaneous Crohn's disease treated with infliximab and 4 years of follow up
- Biological activity of novel progesterone derivatives having a bulky ester side chains at C-3
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- An Open-Label Comparative Study on the Effects of Platelet-Rich Plasma Therapy with Hydroquinone 4% Versus Hydroquinone 4% Alone in Melasma
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol
- 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
- Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
- Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss
- 1262 ONE YEAR FINASTERIDE THERAPY IN MEN WITH A SERUM PSA GREATER THAN 4 NG/ML WHO HAD UNDERGONE REPEAT BIOPSY
- Assessment of The Long-Term Negative Impact of Bariatric Surgery on Health in Saudi Adults, over 3 Years after Surgery: A Cross-Sectional Study
- FUT vs. FUE Graft Survival: A Side-by-Side Study of 3 Patients Undergoing a Routine 2,000+ Graft Hair Transplantation
- 24. 力発揮および操作性からみた下肢運動の一側優位性(神経・感覚,一般口演,第63回日本体力医学会大会)
- Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
- Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3‐month, controlled, assessor‐blinded study
- Efficacy and Tolerability of a Topical Gel Containing Mimicking Growth Factors Oligopeptides, Caffeine, Taurine and an Iron-Chelating Complex in Subjects with Androgenetic Alopecia Treated with Topical Minoxidil or Oral Finasteride: a Prospective, 6-Month, Randomized, Assessor-Blinded, 4-Arm, Parallel Group Study
- Malassezia spp. Overgrowth in a Chinchilla Cat